In the News

Dr. Xingyi Guo worked on a new study that provides novel insights into genetic susceptibility for colorectal cancer in the Journal of the National Cancer Institute.  Dr. Guo tweeted about the study here: https://twitter.com/xingyiguo/status/1695481178571112606 You can read the paper online here: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djad178/…

Andreana Holowatyj, PhD, MSCI, assistant professor of Medicine, has received the National Cancer Institute’s Method to Extend Research in Time (MERIT) Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

Liver cancer, primarily hepatocellular carcinoma (HCC), is the third most common contributor to cancer-related deaths worldwide. Early-stage HCC has a better prognosis than advanced-stage HCC and can be treated with minimally invasive surgery, including robotic-assisted and laparoscopic options. However, few studies have examined the presumably unique and discrepant short-term and long-term outcomes of robotic-assisted and laparoscopic surgeries. Read more.

Polyphenols — antioxidants found in fruits, vegetables, teas and spices — have promising anti-cancer properties. 

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.

A first look into where early onset mortality spikes among U.S. women. Women with early onset colorectal cancer have a greater risk of dying from the disease depending upon their county of residence, according to a study published in Clinical and Translational Gastroenterology.

Breast-conserving surgery (BCS) plus radiotherapy is the standard-of-care for women diagnosed with early-stage breast cancer. For women over age 70, however, radiotherapy after BCS is controversial, and U.S. National Comprehensive Cancer Network clinical practice guidelines recommend that it may be omitted. 

The TAILORx study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence according to a genetic assay test. The study indicated that chemotherapy after surgery provided little advantage in overall survival for these women, so they could forgo the treatment.

Six clinics across four U.S. states provided data for a newly validated clinical risk stratification model for lung cancer. The TREAT model (Thoracic Surgery, Research, Epidemiology, Diagnosis And Treatment) helps identify patients with suspicious lesions who are most likely to benefit from surgical biopsy. The aim is to mitigate unnecessary surgery for benign nodules and reduce delays for patients with early cancers.